SLGC Overview

SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.

Wall Street analysts forecast SLGC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLGC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

SomaLogic, Inc. revenue for the last quarter amounts to NaN USD, decreased

SomaLogic, Inc.. EPS for the last quarter amounts to USD, decreased

SomaLogic, Inc. (SLGC) has 451 emplpoyees as of February 13 2026.

Today SLGC has the market capitalization of 396.23M USD.